The Latest Breaking News from Pfizer

While the S&P 500 Index's dividend yield is just about half of its long-term averages, Ford and Pfizer are two dividend-paying stocks that offer healthy yields. Plus, their cheap valuations mean that there is a reasonable probability of upside over the next couple of years.

These companies are the ones that dominate the market and will continue to do so should factors remain constant.

The drug is the go-to treatment for syphilis and the only one recommended for pregnant people. But a shortage of the injectable drug has prompted some public health agencies to ration it.

Four years after the emergence of Covid-19, the conversation in global public health has moved on from dealing with an immediate crisis to how we can best prepare for the next pandemic.

Any pharmaceutical has risk of side effects, but a COVID infection is far more dangerous than the vaccines

Results confirm how uncommon known complications are as researchers confirm benefits from vaccines still ‘vastly outweigh the risks’

Moderna stock surged Thursday after the firm beat quarterly expectations, including turning around a surprise profit.

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

Pfizer stock is trading at price levels last seen in 2016. The 2025 forecast for PFE stock looks positive, though, and it should go up over the medium to long term.

Read about Pfizer's settlement in the Lipitor antitrust lawsuit, where they have agreed to pay million to resolve the case. Stay informed with our late...

This vivid account of the Hungarian biochemist who endured decades of derision before pioneering Pfizer’s Covid vaccine is a tribute to her tenacity and self-belief